Athenex’s clinical pipeline includes small molecule, biologic, and cell therapies for the treatment of cancer.

Therapy Type/ProgramCandidate/Target AntigensIndicationPre-ClinicalPhase 1Phase 2Phase 3Stage
NKT Cell PlatformKUR-501 – GD2R/R High Risk Neuroblastoma
Phase 1
NKT Cell PlatformKUR-502 – CD19R/R Lymphoma and Leukemia
Phase 1
NKT Cell PlatformKUR-503 – GPC3Advanced HCC
Pre-Clinical
NKT Cell Platformp53, KRAS, EGFRMultiple Tumors
Pre-Clinical
Autologous T CellAutologous TCR-T – NY-ESO-A2Multiple Tumors
Phase 1
Oral paclitaxel and encequidarOral paclitaxel + encequidar w/ dostarlimab*Neoadjuvant Breast Cancer
(I-SPY 2)
Phase 2
Oral paclitaxel and encequidarOral paclitaxel + encequidar w/ pembrolizumabSolid Tumors
Phase 1
TirbanibulinKlisyri® (tirbanibulin ointment)Actinic keratosis
FDA Approved
Phase 3 — FDA Approved
* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline

For more information about our trials, please visit clinicaltrials.gov.